Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00233558 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-04-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX

Conditions

Interventions

DRUG

adalimumab (up to 9 months exposure)

DRUG

methotrexate

Sponsors & Collaborators

Principal Investigators

  • Global Medical Information · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233558 on ClinicalTrials.gov